Laudette Marion, Zuo Haoxiao, Lezoualc'h Frank, Schmidt Martina
Inserm UMR-1048, Institut des Maladies Métaboliques et Cardiovasculaires, Université Toulouse III, 31432 Toulouse, France.
Department of Molecular Pharmacology, University of Groningen, 9713AV Groningen, The Netherlands.
J Cardiovasc Dev Dis. 2018 Feb 3;5(1):9. doi: 10.3390/jcdd5010009.
Evidence collected over the last ten years indicates that Epac and cAMP scaffold proteins play a critical role in integrating and transducing multiple signaling pathways at the basis of cardiac and lung physiopathology. Some of the deleterious effects of Epac, such as cardiomyocyte hypertrophy and arrhythmia, initially described in vitro, have been confirmed in genetically modified mice for Epac1 and Epac2. Similar recent findings have been collected in the lung. The following sections will describe how Epac and cAMP signalosomes in different subcellular compartments may contribute to cardiac and lung diseases.
过去十年收集的证据表明,Epac和环磷酸腺苷(cAMP)支架蛋白在整合和转导心脏和肺部生理病理学基础上的多种信号通路中起着关键作用。Epac的一些有害作用,如最初在体外描述的心肌细胞肥大和心律失常,已在Epac1和Epac2基因敲除小鼠中得到证实。最近在肺部也有类似的发现。以下部分将描述不同亚细胞区室中的Epac和cAMP信号体如何导致心脏和肺部疾病。